CRIS Projected Dividend Yield
Curis Inc ( NASDAQ : CRIS )Curis is a biotechnology company focused on the development of therapeutics for the treatment of cancer. Co.'s clinical stage drug candidates are: Emavusertib, which is being tested in a Phase 1/2 dose escalating clinical trial in patients with non-Hodgkin lymphomas; CI-8993, which is a monoclonal antibody; Fimepinostat, which is a small molecule that potently inhibits the activity of histone deacetylase, and phosphotidyl-inositol 3 kinase; CA-170, for which Co. has announced initial data from a clinical study in patients with mesothelioma in conjunction with the Society of lmmunotherapy of Cancer; and CA-327, which is a small molecule antagonist of PDL1 and TIM3. 20 YEAR PERFORMANCE RESULTS |
CRIS Dividend History Detail CRIS Dividend News CRIS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |